Top Markets
#1 MowCat MowCat +806.41%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.35%
#3 SODAX SODAX +49.28%
#4 Cortex Cortex +28.41%
#5 Pons Pons +20.34%
#6 Magma Finance Magma Finance +18.46%
#7 Akedo Akedo +16.59%
#8 MarsCoin MarsCoin +14.23%
#9 OpenEden OpenEden +13.27%
#10 APEX APEX +12.08%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Avalyn Pharma Inc. Common Stock Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. Common Stock

AVLN
Rank in Stocks #7451
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its... Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Share Price
$35.27
Market Cap
$1.56B
Change (1 day)
-3.40%
Change (1 year)
-
Country
US
Trade Avalyn Pharma Inc. Common Stock (AVLN)

Category

Healthcare
Revenue for Avalyn Pharma Inc. Common Stock (AVLN)
Revenue in Aug 2026 TTM: 0
According to Avalyn Pharma Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Avalyn Pharma Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH